TABLE 2

Paritaprevir pharmacokinetics in plasma and in liver tissue samples from rats receiving 30-mg/kg dosesa

Paritaprevir pharmacokinetic parameterValue
PlasmabTissue samplesc
Surgical resectionCNBFNA5FNA3FNA1
Tmax (h)2.12.15.52.12.12.1
Cmax (ng/ml)3,593125,076100,41275,12547,36856,628
AUC0–24 (ng · h/ml)3,970394,315373,533235,290205,036144,949
t1/2 (h)5.03.04.15.26.14.7
  • a One rat (corresponding to the 4-h time point) was excluded from these analyses because paritaprevir was not at steady state. Abbreviations: CNB, core needle biopsy; FNA1, fine-needle aspiration with 1 pass; FNA3, fine-needle aspiration with 3 passes; FNA5, fine-needle aspiration with 5 passes; AUC, area under the concentration-time curve; Cmax, maximum observed concentration; t1/2, half-life; Tmax, time of maximum observed concentration.

  • b The plasma concentrations corresponding to 24 and 25 h postdose were below the assay's lower limit of quantitation, and their values were thus set at 0.625 ng/ml.

  • c Concentrations measured in tissue samples were converted from nanograms per gram to nanograms per milliliter by using a liver tissue density value for rats of 1.05 g/ml (32).